The first patient has been dosed in a phase 3 trial of Kala Pharmaceuticals’ short-term dry eye treatment KPI-121 0.25%, the company announced in a press release.
The STRIDE 3 multicenter, randomized, double-masked, placebo-controlled, parallel arm trial will compare KPI-121 0.25% to placebo in approximately 900 patients with dry eye, with the primary endpoint being patient report of discomfort severity at day 15. Patients will be dosed four times a day for 14 days.
“If approved, KPI-121 0.25% could be the first FDA- approved product for the short-term treatment of (Read more...)
Uncategorized